RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Abingworth
A

Abingworth portfolio

Abingworth has 6 portfolio companies on record at Recent Funding, with 3 investments in the last 12 months.

Website: abingworth.com.
Type: Venture capital.
Portfolio on Recent Funding: 6.
Deals, last 12 months: 3.
Rounds led: 6 of 8.
Capital in their rounds: $954.44M.
Latest deal: AdvanCell · Jul 15, 2026.
About this page

It is a venture capital firm based in London, GB, founded in 1987. It led 6 of the 8 rounds it joined. Its most recent investment on record is AdvanCell's $315M Series B+ round in July 2026, alongside Fidelity Management & Research Company, Morningside, Eli Lilly and 15 others. By category, its portfolio leans toward Health and bio (6) and Manufacturing and industrial (1). It has co-invested with Sanofi Ventures, SymBiosis and Brandon Capital, most often Sanofi Ventures (4 rounds).

About Abingworth

Firm type: Venture capital.
Headquarters: London, GB.
Founded: 1987.
Stages: Seed, Series A, Series B, Series C, Growth, Late Stage.
Sectors: Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Check size: $15M to $30M.

What Abingworth invests in

Abingworth recent investments

CompanyRoundDateAlongside
AAdvanCellSeries B+ · $315MFidelity Management & Research Company, Morningside, Eli Lilly +15
RR1 TherapeuticsSeries A · $77.5M · leadDaVita Venture Group (lead), U.S. Renal Care, SymBiosis +2
AAddition TherapeuticsSeries A · $100M · leadOUP, Bill & Melinda Gates Foundation, SR One (lead) +2
GGlycomineSeries B+ · $115MAdvent Life Sciences (lead), RiverVest, Novo Holdings +6
AAdvanCellSeries B+ · $112M · leadMorningside, SymBiosis (lead), Brandon Capital +3
MMyricx BioSeries A · $120M · leadCancer Research Horizons, Novo Holdings (lead), Eli Lilly +3
GGlycomineSeries B+ · $68M · leadRiverVest, Novo Holdings, Sanderling Ventures +5
NNouscomSeries B+ · $46.94M · leadLSP BioVentures, 5AM Ventures, Versant Ventures

How Abingworth invests

StageDealsCapital in rounds
Series B+ 5 63%$656.94M
Series A 3 38%$297.5M
YearDealsCapital in rounds
2017 1 13%$46.94M
2021 1 13%$68M
2024 1 13%$120M
2025 3 38%$327M
2026 2 25%$392.5M

Abingworth portfolio companies

CompanyRound with AbingworthTotal raisedLatest raise
AAdvanCell
Health and bio
Series B+ · $315M$439.5MJul 15, 2026
Series B+
RR1 Therapeutics
Health and bio
Series A · $77.5M · lead$158MSep 30, 2026
Series A
AAddition Therapeutics
Health and bio
Series A · $100M · lead$100MDec 17, 2025
Series A
GGlycomine
Health and bio
Series B+ · $115M$195MMay 9, 2025
Series B+
MMyricx Bio
Health and bio
Series A · $120M · lead$120MJul 8, 2024
Series A
NNouscom
Health and bio
Series B+ · $46.94M · lead$267.56MOct 19, 2026
Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Share is of the 8 rounds on Recent Funding that name Abingworth. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Abingworth, which is a subset of its real portfolio. API: /api/v1/investors/abingworth (get a free API key). More: the most active VC firms and new venture capital funds.

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy